Effect of Lipikar Urea 30% Before Actinic Keratoses Treatment

Summary

This study is conducted in one center in Germany, in adult subjects having actinic keratoses (grade I or II) lesions on the scalp and meeting specific inclusion/exclusion criteria. The purpose of the study is to evaluate a holistic management (efficacy, tolerability and lesion cosmetic outcomes) of Tolak® treatment.

Eligibility

Inclusion Criteria:

* diagnosis of at least 4 non-hypertrophic, non-hyperkeratotic actinic keratosis of the the scalp
* planned treatment of actinic keratoses of the scalp with Tolak®
* Olsen grade I or II

Exclusion Criteria:

* known or documented intolerance to any of the ingredients of Tolak® or Lipikar Urea 30%
* treatment of actinic keratoses in the treatment area within the past 3 months (e.g. photodynamic therapy, topical 5-FU, diclofenac, imiquimod, cryotherapy etc.)
* suspected invasive squamous cell cancer in the treatment area
* chronic wounds, erosions, pre-existing inflamed or infected skin with disruption of the epidermal barrier in the treatment area current or within the last 8 weeks given systemic cancer medication or systemic treatment with 5-Fluorouracil

Conditions2

Browse More Trials